샘플 요청 목록

 카트 문의
시장보고서
상품코드
1768464

세계의 색전요법 시장

Embolotherapy
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 282 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 색전요법 시장은 2030년까지 85억 달러에 달할 전망

2024년에 54억 달러로 추정되는 세계의 색전요법 시장은 분석 기간인 2024-2030년에 CAGR 7.7%로 성장하며, 2030년에는 85억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 색전제는 CAGR 8.2%를 기록하며, 분석 기간 종료시에는 67억 달러에 달할 것으로 예측됩니다. 지원 기기 부문의 성장률은 분석 기간 중 CAGR 5.8%로 추정됩니다.

미국 시장은 14억 달러, 중국은 CAGR 11.3%로 성장 예측

미국의 색전요법 시장은 2024년에 14억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 21억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 11.3%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.0%와 7.1%로 예측됩니다. 유럽에서는 독일이 CAGR 4.8%로 성장할 것으로 예측됩니다.

세계의 색전요법 시장 - 주요 동향과 촉진요인 정리

색전술은 최소침습적 치료에 어떤 혁명을 일으키고 있는가?

최첨단 최소침습 치료법인 색전술은 표적 부위로의 혈류를 효과적으로 차단하여 암, 혈관 이상, 외상으로 인한 출혈 등 다양한 복잡한 증상의 치료를 촉진하고 의료의 전망을 재정의하고 있습니다. 초기에는 소화관 출혈과 외상 관리에 사용되었지만, 색전술은 크게 발전하여 종양학, 여성 건강 등의 분야에도 적용이 확대되고 있습니다. 종양학에서는 경동맥화학색전술(TACE)과 방사성 색전술이 간암 치료에 널리 사용되고 있으며, 종양에서 혈액 공급을 차단하는 동시에 국소 화학요법을 시행하여 주변 조직의 손상을 최소화하고 있습니다. 마찬가지로 자궁근종 색전술은 비수술적 해결책을 원하는 여성들에게 자궁적출술의 대안으로 덜 침습적이고 회복이 빠른 방법으로 선호되고 있습니다. 이 외에도 색전술은 정맥류 치료, 동맥 기형 관리, 응급 외상 환자에서 출혈을 조절하는 데에도 자주 사용되어 의료진에게 복잡한 시나리오에서 효율적이고 종종 생명을 구할 수 있는 옵션을 제공합니다.

색전술은 주요 용도 외에도 기존 수술에 적합하지 않은 고위험군 환자를 관리할 수 있는 능력으로 인정받고 있습니다. 저침습적이기 때문에 합병증 위험을 줄이고, 입원 기간을 단축하며, 회복 시간을 단축할 수 있습니다. 이 치료법은 외래나 중환자실에서 환자 개개인의 필요에 맞게 조정할 수 있는 다용도한 특성으로 인해 의료 서비스 프로바이더들 사이에서 인기를 끌고 있습니다. 또한 외상의 경우, 색전술의 신속한 전개와 내출혈의 정확한 제어는 추가 중재를 위해 환자를 안정화시킬 수 있습니다. 이러한 장점으로 인해 색전술은 중재적 영상의학에서 매우 중요한 기술로 남아 있으며, 환자 중심의 치료에 중점을 둔 복잡한 병태생리를 관리하는 데 있으며, 점점 더 중요한 역할을 할 것으로 예측됩니다.

색전술을 발전시키는 기술적 진보는 무엇인가?

최근 영상 처리 및 카테터 시스템의 기술 혁신은 색전술을 새로운 차원으로 끌어올리고, 시술의 안전성과 정확성을 높이며, 다양한 임상 상황에서 더욱 효과적으로 사용할 수 있도록 하고 있습니다. 고화질 투시, MRI 유도하 중재술, 3D 영상과 같은 영상 진단의 발전으로 의료진은 표적 부위를 놀랍도록 세밀하게 볼 수 있고, 색전제를 정확하게 투여할 수 있으며, 주변 건강한 조직에 미치는 영향을 최소화할 수 있습니다. 이러한 이미징의 향상과 함께 색전 물질 자체도 진화하고 있으며, 약제용출성 비드나 생분해성 마이크로스피어와 같은 혁신적인 옵션은 두 가지 이점을 제공합니다. 이러한 첨단 재료는 혈류를 차단하는 동시에 국소 약물 치료를 통해 종양 및 기타 복잡한 병리를 치료하기 위한 보다 종합적인 접근을 가능하게 합니다. 영상 기술과 첨단 재료의 조합은 환자의 예후를 크게 개선하고 색전술의 적용 가능성을 넓힐 수 있습니다.

또 다른 주요 발전은 카테터 기술의 발전으로, 마이크로카테터와 조종 가능한 카테터의 새로운 설계로 복잡한 혈관 네트워크 내에서의 내비게이션이 향상되었습니다. 이러한 수준의 제어는 뇌와 같은 민감한 부위의 종양이나 비정상적인 혈관을 표적으로 삼는 것과 같이 정밀한 정확도가 요구되는 시술에 필수적입니다. 또한 로봇을 이용한 색전술은 새로운 동향이며, 임상의가 복잡한 시술을 보다 정확하게 수행하고 방사선 노출을 줄일 수 있도록 돕습니다. 인공지능(AI)과 머신러닝을 색전술에 통합하여 치료 결과에 대한 예측적 인사이트를 제공하고 맞춤형 치료 계획을 안내할 수 있는 방안도 검토되고 있습니다. 이러한 기술적 진보를 종합하면 색전술은 정확하고 효과적인 치료 옵션으로 변모하여 진화하는 현대 의료의 요구에 부응하고 최소침습적 치료의 가능성을 넓혀가고 있습니다.

왜 색전술의 새로운 최종 용도가 등장하고 있는 것일까?

색전술의 적용 범위는 다양한 치료 영역에서 빠르게 확대되고 있습니다. 그 주요 이유는 저침습적이고 도달하기 어려운 병태의 치료에 효과적이기 때문입니다. 예를 들어 종양학에서 이 시술은 간암뿐만 아니라 신장암, 전립선암 및 기타 유형의 종양에도 효과적임이 입증되어 환자에게 기존 수술에 대한 보다 덜 침습적이고 부작용이 적은 대안을 제공합니다. 이 시술은 외상 치료에서도 보편화되고 있으며, 내출혈을 억제할 수 있으며, 다른 외과적 개입을 시행하기 전에 환자를 안정시키는 중요한 수단으로 활용되고 있습니다. 여성 건강 분야에서 색전술은 자궁근종 색전술과 같은 시술로 자궁 적출술의 대안으로 빠른 회복과 위험이 적은 비수술적 해결책을 원하는 환자들에게 어필하고 있습니다. 이러한 용도는 색전술이 여러 의료 분야에서 근본적인 치료법이 될 수 있는 가능성을 강조하고 있습니다.

색전술은 동정맥 기형(AVM) 치료, 비정상적인 혈류 조절을 통한 동맥류 예방 등 심혈관에 적용될 수 있는 다양한 용도가 있습니다. 맞춤형 의료가 계속 성장하고 있는 가운데, 이 치료법의 적응성은 환자의 고유한 요구에 맞게 조정할 수 있으며, 색전제와 표적 치료제를 결합할 수 있는 가능성을 제공합니다. 이러한 개인화된 접근 방식은 임상의가 환자 개개인의 프로파일에 맞는 시술을 할 수 있게 함으로써 치료 영역이 더욱 확장될 것으로 기대됩니다. 또한 색전술은 정확성과 최소 침습성으로 인해 섬세한 구조에 적합하므로 소화기 및 비뇨기 계통의 치료에도 적용되고 있습니다. 이 기술의 광범위한 채택은 환자의 예후를 개선할 뿐만 아니라, 의료진이 점점 더 다양한 질환에 대한 고급 치료 옵션을 제공할 수 있게 함으로써 색전술이 현대 중재적 의학에서 중요한 역할을 하게 되었습니다.

색전요법 세계 시장 성장 원동력은?

색전술 시장의 성장은 주로 기술 발전, 최종 용도 확대, 의료 선호도의 진화에 기반한 여러 요인에 의해 주도되고 있습니다. 고화질 영상과 정교한 카테터 디자인과 같은 기술 혁신은 시술의 정확성을 향상시켜 다양한 치료 분야에서 색전술이 신뢰할 수 있는 선택이 되고 있습니다. 이는 특히 종양학 분야와 관련이 있으며, 이 시술의 최소 침습성과 종양 표적화 효과로 인해 특히 간암과 신장암의 경우 채택이 증가하고 있습니다. 또한 약제용출성 및 생분해성 색전제의 개발로 치료의 폭이 넓어지면서 혈액 공급을 차단하고 국소 약물 요법을 시행하는 이중 작용 접근법이 가능해졌습니다.

최종 용도의 확대도 시장 성장에 중요한 역할을 하고 있으며, 색전술은 외상 치료, 여성 건강, 심혈관, 비뇨기과, 소화기 등 신흥 분야에서의 사용도 증가하고 있습니다. 또한 환자 중심의 의료 동향과 최소 침습 수술에 대한 수요 증가로 인해 환자들이 회복 시간이 짧고 합병증 위험이 낮은 대체 의료를 원하고 있으며, 더욱 확산되고 있습니다. 인구 고령화와 암 및 혈관 질환을 포함한 만성질환의 발병률 증가는 효과적이고 표적화된 중재로서 색전술에 대한 수요를 지원하고 있습니다. 의료 프로바이더와 제조업체의 전략적 협력 관계는 혁신을 촉진하고 특히 신흥 시장에서 첨단 솔루션을 전 세계에서 쉽게 이용할 수 있도록 함으로써 시장 성장을 지원하고 있습니다. 이러한 요인들이 복합적으로 작용하여 색전술은 기술 혁신, 용도 확대, 현대 의료의 정밀하고 최소 침습적인 치료로의 전환을 통해 지속적인 성장을 이룰 것으로 예측됩니다.

부문

제품 부문(색전제, 지원 디바이스); 적응 질환(암, 말초혈관 질환, 신경질환, 비뇨기·신장질환, 소화기 질환)

조사 대상 기업의 예

  • Abbott Laboratories
  • Acandis GmbH
  • Balt Extrusion
  • Boston Scientific Corporation
  • BTG PLC
  • Cook Medical
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic PLC
  • Meril Life Sciences Pvt., Ltd.
  • Merit Medical Systems
  • Penumbra, Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.17

Global Embolotherapy Market to Reach US$8.5 Billion by 2030

The global market for Embolotherapy estimated at US$5.4 Billion in the year 2024, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Embolic Agents, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth in the Support Devices segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.3% CAGR

The Embolotherapy market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Embolotherapy Market - Key Trends & Drivers Summarized

How Is Embolotherapy Revolutionizing Minimally Invasive Treatments?

Embolotherapy, a cutting-edge minimally invasive procedure, is redefining the landscape of medical treatments by effectively blocking blood flow to targeted areas, facilitating treatment for a variety of complex conditions such as cancer, vascular anomalies, and trauma-related bleeding. Initially employed to manage gastrointestinal bleeding and traumatic injuries, embolotherapy has evolved significantly, with applications expanding to fields like oncology and women’s health. In oncology, transarterial chemoembolization (TACE) and radioembolization are widely used for liver cancer treatment, depriving tumors of blood supply while delivering localized chemotherapy, minimizing damage to surrounding tissues. Similarly, uterine fibroid embolization has emerged as a preferred alternative to hysterectomy for women seeking non-surgical solutions, offering a less invasive, quicker recovery pathway. Beyond these areas, embolotherapy has become a popular choice in treating varicose veins, managing arterial malformations, and controlling bleeding in emergency trauma cases, providing healthcare providers with an efficient and often life-saving option in complex scenarios.

Beyond its primary applications, embolotherapy is recognized for its ability to manage high-risk patients who may not be ideal candidates for traditional surgical procedures. With its minimally invasive nature, the procedure reduces the overall risk of complications, shortens hospital stays, and decreases recovery time, factors that resonate with patient preferences for treatment. The procedure’s versatility allows it to be tailored to individual patients’ needs, whether in outpatient settings or within intensive care environments, which has broadened its appeal among healthcare providers. Additionally, in trauma cases, embolotherapy’s rapid deployment and precision in controlling internal bleeding can stabilize patients for further interventions. Given these benefits, embolotherapy continues to be a pivotal technique within interventional radiology and is projected to play an increasingly prominent role in managing complex medical conditions with a focus on patient-centered care.

What Technological Advancements Are Propelling Embolotherapy Forward?

Recent technological breakthroughs in imaging and catheter systems are propelling embolotherapy to new heights, making procedures safer, more precise, and increasingly effective across various clinical settings. Imaging advancements, such as high-definition fluoroscopy, MRI-guided intervention, and 3D imaging, allow healthcare providers to visualize target areas with remarkable detail, ensuring embolic agents are precisely deployed and minimizing impact on surrounding healthy tissue. Alongside these imaging enhancements, embolic materials themselves have evolved, with innovative options like drug-eluting beads and biodegradable microspheres offering dual benefits. These advanced materials block blood flow while simultaneously delivering localized drug therapy over time, enabling a more comprehensive approach to treating tumors and other complex conditions. The combination of imaging technology and advanced materials significantly enhances patient outcomes and broadens the potential applications of embolotherapy.

Another key development is the evolution of catheter technology, with new designs in micro and steerable catheters improving navigation within intricate vascular networks. This level of control is essential in procedures requiring pinpoint accuracy, such as those targeting tumors or abnormal blood vessels in sensitive areas like the brain. Additionally, robotic-assisted embolotherapy is an emerging trend, allowing clinicians to perform complex procedures with increased precision and reduced radiation exposure. The integration of artificial intelligence (AI) and machine learning in embolotherapy is also on the horizon, offering predictive insights into procedure outcomes, which can guide customized treatment plans. Collectively, these technological advancements are transforming embolotherapy into a highly precise, effective treatment option, meeting the evolving demands of modern healthcare and expanding the possibilities for minimally invasive interventions.

Why Are New End-Use Applications for Embolotherapy Emerging?

The scope of embolotherapy is rapidly expanding across a variety of therapeutic areas, largely due to its minimally invasive nature and effectiveness in treating hard-to-reach conditions. In oncology, for example, the procedure has proven effective not only for liver cancer but also for renal, prostate, and other types of tumors, offering patients less invasive alternatives to traditional surgery with fewer side effects. This technique is also becoming more common in trauma care, where its capacity to control internal bleeding makes it a critical tool in stabilizing patients before other surgical interventions. In women’s health, embolotherapy is gaining traction with procedures like uterine fibroid embolization, providing a non-surgical solution that appeals to patients seeking alternatives to hysterectomy, with quicker recovery times and less risk involved. These applications highlight embolotherapy’s potential to become a cornerstone treatment in multiple medical fields.

The versatility of embolotherapy extends to cardiovascular applications, where it is used to treat arteriovenous malformations (AVMs) and prevent aneurysms by regulating abnormal blood flow. As personalized medicine continues to grow, the procedure's adaptability enables it to align with patient-specific needs, offering the possibility of combining embolic agents with targeted therapies. This personalized approach is expected to support further expansion in treatment areas, as clinicians can tailor procedures to individual patient profiles. Additionally, embolotherapy is seeing applications in gastrointestinal and urological treatments, as its precision and minimal invasiveness make it suitable for delicate structures. The broader adoption of this technique is not only improving patient outcomes but also enabling healthcare providers to offer advanced treatment options across an increasing array of medical conditions, reinforcing embolotherapy’s role as a critical tool in modern interventional medicine.

What’s Driving the Growth of the Global Embolotherapy Market?

The growth in the embolotherapy market is driven by several factors, primarily rooted in technological advancements, expanding end-use applications, and evolving healthcare preferences. Technological innovations such as high-definition imaging and sophisticated catheter designs have enhanced procedural precision, making embolotherapy a reliable choice across various therapeutic fields. This is particularly relevant in oncology, where the procedure’s minimally invasive nature and effectiveness in tumor targeting have led to increased adoption, especially in cases of liver and renal cancers. Furthermore, the development of drug-eluting and biodegradable embolic agents has broadened the scope of treatments, allowing for dual-action approaches that block blood supply and deliver localized drug therapy, a feature gaining traction in the oncology sector.

End-use expansion also plays a significant role in market growth, with embolotherapy being increasingly used in trauma care, women's health, cardiovascular applications, and even emerging fields like urology and gastroenterology. Additionally, the trend towards patient-centered healthcare and the growing demand for minimally invasive procedures are further fueling adoption, as patients increasingly seek alternatives with shorter recovery times and lower complication risks. An aging population and rising incidence of chronic diseases, including cancer and vascular disorders, underpin the demand for embolotherapy as an effective, targeted intervention. Strategic collaborations between healthcare providers and manufacturers also support market growth by fostering innovation and making advanced solutions more accessible globally, especially in emerging markets. Together, these factors are positioning embolotherapy for sustained growth, driven by innovation, expanding applications, and a shift towards precision and minimally invasive treatments in modern healthcare.

SCOPE OF STUDY:

The report analyzes the Embolotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Segment (Embolic Agents, Support Devices); Disease Indication (Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders, Gastrointestinal Disorders)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Acandis GmbH
  • Balt Extrusion
  • Boston Scientific Corporation
  • BTG PLC
  • Cook Medical
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic PLC
  • Meril Life Sciences Pvt., Ltd.
  • Merit Medical Systems
  • Penumbra, Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Embolotherapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Cancer and Vascular Disorders Expands the Addressable Market for Minimally Invasive Embolotherapy Solutions
    • Increasing Adoption of Minimally Invasive Medical Interventions Spurs Growth in Embolotherapy Techniques Across Key Healthcare Markets
    • Technological Advancements in Embolic Agents Improve Precision and Effectiveness, Driving Broader Adoption of Embolotherapy Solutions
    • Expanding Geriatric Population with Increased Risk of Vascular and Cancer-Related Conditions Propels Market Demand for Embolotherapy Procedures
    • Growing Awareness of Uterine Fibroid Embolization as a Non-Surgical Alternative to Hysterectomy Strengthens the Market for Womens Health Applications
    • Rising Prevalence of Arteriovenous Malformations (AVMs) Drives the Need for Specialized Embolotherapy Solutions to Treat Complex Vascular Malformations
    • Shift Toward Outpatient and Ambulatory Care Settings for Embolotherapy Procedures Expands Access and Drives Cost-Effective Healthcare Delivery
    • Growing Use of Embolization Techniques as Less Invasive Alternatives to Open Surgery in Trauma Cases Boosts Demand for Specialized Embolotherapy Solutions
    • Improved Biocompatibility of Next-Generation Embolic Materials Expands Usage in Multi-Therapeutic Applications, Including Oncology and Gynecology
    • Innovations in Catheter Technologies and Delivery Systems Improve Precision and Safety of Embolotherapy Procedures, Supporting Market Growth
    • Increased Adoption of Drug-Eluting Beads in Embolotherapy Enhances Efficacy in Cancer Treatment, Creating New Growth Opportunities in Oncology
    • Rising Global Healthcare Expenditures and Improved Access to Quality Care Drive Demand for Embolotherapy Solutions in Developed and Emerging Markets
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Embolic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Support Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Peripheral Vascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Urological & Nephrological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Gastrointestinal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Embolotherapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • JAPAN
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • CHINA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • EUROPE
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • FRANCE
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • GERMANY
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Embolotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • INDIA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Embolotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Embolotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • AFRICA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제